Literature DB >> 33428327

Strategies To Design Selective Histone Deacetylase Inhibitors.

Jelena Melesina1, Conrad V Simoben1, Lucas Praetorius1, Emre F Bülbül1, Dina Robaa1, Wolfgang Sippl1.   

Abstract

This review classifies drug-design strategies successfully implemented in the development of histone deacetylase (HDAC) inhibitors, which have many applications including cancer treatment. Our focus is on especially demanded selective HDAC inhibitors and their structure-activity relationships in relation to corresponding protein structures. The main part of the paper is divided into six subsections each narrating how optimization of one of six structural features can influence inhibitor selectivity. It starts with the impact of the zinc binding group on selectivity, continues with the optimization of the linker placed in the substrate binding tunnel as well as the adjustment of the cap group interacting with the surface of the protein, and ends with the addition of groups targeting class-specific sub-pockets: the side-pocket-, lower-pocket- and foot-pocket-targeting groups. The review is rounded off with a conclusion and an outlook on the future of HDAC inhibitor design.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  chemical epigenetics; drug design; histone deacetylases; pharmacophore; structure-activity relationships

Mesh:

Substances:

Year:  2021        PMID: 33428327     DOI: 10.1002/cmdc.202000934

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  9 in total

1.  Novel HDAC1 and HDAC2 Inhibitors for Treating Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-09-21       Impact factor: 4.632

2.  Development of a Cellular Model Mimicking Specific HDAC Inhibitors.

Authors:  Lena Hess; Verena Moos; Christian Seiser
Journal:  Methods Mol Biol       Date:  2023

3.  Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.

Authors:  Mohamed Abdelsalam; Hany S Ibrahim; Lukas Krauss; Matthes Zessin; Anita Vecchio; Sieglinde Hastreiter; Mike Schutkowski; Günter Schneider; Wolfgang Sippl
Journal:  Methods Mol Biol       Date:  2023

4.  Lysine Deacetylase Substrate Selectivity: A Dynamic Ionic Interaction Specific to KDAC8.

Authors:  Tasha B Toro; Jordan S Swanier; Jada A Bezue; Christian G Broussard; Terry J Watt
Journal:  Biochemistry       Date:  2021-08-06       Impact factor: 3.321

5.  Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors.

Authors:  Emre F Bülbül; Jelena Melesina; Hany S Ibrahim; Mohamed Abdelsalam; Anita Vecchio; Dina Robaa; Matthes Zessin; Mike Schutkowski; Wolfgang Sippl
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.411

6.  Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies.

Authors:  Hong Phuong Nguyen; Quang De Tran; Cuong Quoc Nguyen; Tran Phuong Hoa; Tran Duy Binh; Huynh Nhu Thao; Bui Thi Buu Hue; Nguyen Trong Tuan; Quang Le Dang; Nguyen Quoc Chau Thanh; Nguyen Van Ky; Minh Quan Pham; Su-Geun Yang
Journal:  RSC Adv       Date:  2022-08-10       Impact factor: 4.036

Review 7.  A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.

Authors:  Anna Fontana; Ilaria Cursaro; Gabriele Carullo; Sandra Gemma; Stefania Butini; Giuseppe Campiani
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

8.  The Effect of Vicinal Difluorination on the Conformation and Potency of Histone Deacetylase Inhibitors.

Authors:  A Daryl Ariawan; Flora Mansour; Nicole Richardson; Mohan Bhadbhade; Junming Ho; Luke Hunter
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 9.  Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.

Authors:  Dusan Ruzic; Nemanja Djoković; Tatjana Srdić-Rajić; Cesar Echeverria; Katarina Nikolic; Juan F Santibanez
Journal:  Pharmaceutics       Date:  2022-01-16       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.